<DOC>
	<DOCNO>NCT02187133</DOCNO>
	<brief_summary>This study conduct Phase Ib , open-label , non-randomized , single-institution study evaluate safety tolerability carfilzomib combination bendamustine rituximab patient relapse refractory NHL determine recommend phase II dose preliminary efficacy combination . The study two phase : dose-escalation phase determine maximal tolerate dose carfilzomib combination participant monitor toxicity , tolerability response dose-expansion phase determine preliminary efficacy patient Mantle cell lymphoma disease subtype preliminary efficacy signal observe . Determination maximum tolerate dose ( MTD ) follow standard 3+3 design escalation carfilzomib dose ( Table 5.2 ) . Dose level carfilzomib 15 mg/m2 , 20 mg/m2 , 27 mg/m2 , 36 mg/m2 IV administer day 1 , 2 , 8 , 9 , 15 16 . The last 2 cohort start carfilzomib dose 20 mg/m2 day 1 , 2 . Bendamustine administer well-tolerated dose 90 mg/m2 IV day 1 2 . A dose de-escalation bendamustine 75 mg/m2 ( cohort -1 ) occur start dose prof intolerable combination . Rituximab give dose 375 mg/m2 day 9 Cycle 1 day 1 subsequent cycle . Rituximab intentionally delay day 9 cycle 1 help facilitate performance correlative study .</brief_summary>
	<brief_title>Carfilzomib With Bendamustine Rituximab Patients With Relapsed Refractory Non-Hodgkin Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<criteria>Histologicallyconfirmed Bcell nonHodgkin 's lymphoma ( Mantle Cell Lymphoma , Follicular Lymphoma , Small Lymphocytic Lymphoma/Chronic Lymphocytic Leukemia , Marginal Zone Lymphoma , Diffuse Large Bcell Lymphoma , Lymphoplasmacytic Lymphoma ) Must relapse refractory disease 2 4 prior line therapy ; 1 line therapy allow , include autologous stem cell transplant least 12 week elapse Day 0 . A line therapy define course therapy interrupt progressive disease . Subjects must measurable disease least 1.5 cm diameter Age ≥ 18 year Life expectancy ≥ 3 month Eastern Cooperative Oncology Group ( ECOG ) performance status 02 Laboratory : Adequate bone marrow function : Absolute neutrophil count ≥ 1.0 × 109/L Hemoglobin ≥ 8 g/dL ( 80 g/L ) within 14 day prior Cycle 1 , Day 1 ( subject may receive red blood cell [ RBC ] transfusion accordance institutional guideline ) Platelet count ≥ 75 × 109/L or≥ 50× 109/L lymphoma involvement bone marrow , independent platelet transfusion Adequate hepatic function : Serum AST/ALT ≤ 3 time upper limit normal Serum direct bilirubin ≤ 2 mg/dL ( unless history Gilbert 's ) Adequate renal function : Creatinine clearance ( CrCl ) ≥ 30 mL/minute , either measure calculate use standard formula ( eg , Cockcroft Gault ) Uric acid If elevate , correct within laboratory range prior dose Females childbearing potential ( FCBP ) must agree ongoing pregnancy test practice contraception . FCBP definition : A female childbearing potential sexually mature woman : 1 ) undergone hysterectomy bilateral oophorectomy ; 2 ) naturally postmenopausal least 24 consecutive month . Male subject must agree practice contraception . Progressive disease bendamustine within 6 month cycle 1 , Day 1 Prior treatment carfilzomib lymphoma Patient receive investigational drug within 21 day prior Cycle 1 , Day 1 . Exceptions allow great four halflives experimental agent ) . Prior radiation therapy chemotherapy within 2 week prior Cycle 1 , Day 1 , monoclonal antibody therapy within 4 week Prior allogeneic transplant Active , uncontrolled CNS involvement lymphoma Pregnant lactating female Major surgery within 14 day prior Cycle 1 , Day 1 Acute active infection require treatment ( systemic antibiotic , antiviral , antifungal ) within 14 day prior Cycle 1 , Day 1 Known human immunodeficiency virus infection Active hepatitis B C infection , define presence HBV surface antigen HCV antibody . Subjects HBVsAg antibody positive allow study long HBVsAg negative require HBV PCR monitor per institutional standard . Unstable angina myocardial infarction within 6 month prior Cycle 1 , Day 1 , NYHA Class III IV heart failure , LVEF &lt; 40 % , uncontrolled angina , history severe coronary artery disease , history torsade de pointes , history symptomatic pulmonary hypertension , severe uncontrolled ventricular arrhythmia , sick sinus syndrome , QTc prolongation &gt; 450 msec , electrocardiographic evidence acute ischemia Grade 3 conduction system abnormalities unless subject pacemaker . Uncontrolled hypertension uncontrolled diabetes within 14 day prior Cycle 1 , Day 1 Nonhematologic malignancy within past 3 year exception ) adequately treat basal cell carcinoma , squamous cell skin cancer , thyroid cancer ; b ) carcinoma situ cervix breast ; c ) prostate cancer Gleason Grade 6 less stable prostatespecific antigen level ; ) cancer consider cure surgical resection unlikely impact survival duration study , localize transitional cell carcinoma bladder benign tumor adrenal pancreas Significant neuropathy ( Grades 34 , Grade 2 pain ) within 14 day prior Cycle 1 , Day 1 Known history allergy Captisol® ( cyclodextrin derivative use solubilize carfilzomib ) Contraindication require concomitant drug supportive treatment , include hypersensitivity anticoagulation antiplatelet option , antiviral drug , intolerance hydration due preexist pulmonary cardiac impairment Subjects pleural effusion require thoracentesis ascites require paracentesis within 14 day prior Cycle 1 , Day 1 Any clinically significant medical disease condition , Investigator 's opinion , may interfere protocol adherence subject 's ability give inform consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Relapsed</keyword>
	<keyword>Refractory</keyword>
</DOC>